287176-62-9

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-2-CHLOROQUINOLINE-4-CARBOXYLIC ACID, 97 is used as an intermediate in the synthesis of pharmaceuticals for its role in the production of anti-inflammatory and anti-cancer drugs. Its unique chemical structure contributes to the development of medications that target specific biological pathways, offering potential therapeutic benefits in treating various diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 6-BROMO-2-CHLOROQUINOLINE-4-CARBOXYLIC ACID, 97 is utilized as a key component in the development of crop protection agents. Its application aids in enhancing crop yield and quality by protecting plants from pests and diseases, thereby contributing to sustainable agriculture practices.
Used in Organic Synthesis and Research:
6-BROMO-2-CHLOROQUINOLINE-4-CARBOXYLIC ACID, 97 serves as a versatile building block in organic synthesis due to its reactivity and compatibility with various solvents and reagents. It is employed in research laboratories for the exploration of new chemical reactions and the synthesis of novel compounds with potential applications in various fields.

Upstream product

• 5463-29-6 6-bromo-2-hydroxyquinoline-4-carboxylic acid 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors

A series of imidazo[1,5-a]quinoline derivatives was designed and synthesized as central benzodiazepine receptor (CBR) ligands. Most of the compounds showed high CBR affinity with Ki values within the submicromolar and subnanomolar ranges with interesting modulations in their structure-affinity relationships. In particular, fluoroderivative 7w (Ki = 0.44 nM) resulted in the most potent ligand among the imidazo[1,5-a]quinoline derivatives described so far. Overall, these observations confirmed the assumption concerning the presence of a large though apparently saturable lipophilic pocket in the CBR binding site region interacting with positions 4 and 5 of the imidazo[1,5-a]quinoline nucleus. The in vivo biological characterization revealed that compounds 7a,c,d,l,m,q,r,w show anxiolytic and antiamnestic activities without the unpleasant myorelaxant side effects of the classical 1,4-BDZ. Furthermore, the effect of 7l,q,r, and 8i in lowering lactate dehydrogenase (LDH) release induced by ischemia-like conditions in rat brain slices suggested neuroprotective properties for these imidazo[1,5-a]quinoline derivatives.